Roth Capital Has Pessimistic View of BRTX FY2028 Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Analysts at Roth Capital dropped their FY2028 earnings estimates for BioRestorative Therapies in a report issued on Monday, February 10th. Roth Capital analyst J. Aschoff now expects that the company will earn $5.24 per share for the year, down from their prior forecast of $5.40. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.43) per share. Roth Capital also issued estimates for BioRestorative Therapies’ FY2029 earnings at $6.93 EPS.

BioRestorative Therapies (NASDAQ:BRTX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.22. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%. The firm had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.30 million.

BioRestorative Therapies Price Performance

BRTX opened at $2.44 on Tuesday. The company’s 50 day moving average is $1.79 and its 200 day moving average is $1.66. BioRestorative Therapies has a 12-month low of $1.03 and a 12-month high of $2.55.

BioRestorative Therapies Company Profile

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.